Sunshine Biopharma Inc. (SBFM)
NASDAQ: SBFMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SBFM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.84M
- Forward P/E
- 0.01
- EPS (TTM)
- -$620.60
- Dividend yield
- None
- 52-week range
- 2.23 – 464.00
- Day range
- 2.23 – 2.35
- Volume / Avg
- 22.93K / 301.48K
- Beta
- —
- Shares outstanding
- 823.77K
52-week range
SBFM stock today
Sunshine Biopharma (SBFM) closed at $2.23 on Nov 20, down 5.11% (-$0.12), versus the S&P 500's 3.70% decline. Trading was light, with 22.93K shares changing hands, about 8% of the average daily volume. At this level, SBFM sits near the bottom of its 52-week range of $2.23 to $464.00: 99.5% below the high and 0.0% above the low.
Sunshine Biopharma has posted a net loss over the last twelve months (EPS of -$620.60), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Sunshine Biopharma
Company profileSunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Steve N. Slilaty Ph.D.
- Headquarters
- Fort Lauderdale, FL
- Employees
- 50
- Website
- sunshinebiopharma.com
Financial highlights
Full financialsIn fiscal 2025, Sunshine Biopharma generated $36.3 million in revenue, up 4.1% from fiscal 2024, its 7th consecutive year of revenue growth. Sunshine Biopharma reported a net loss of $6.0 million, compared with a loss of $5.1 million a year earlier. Gross margin was 33.8% (up from 30.6%) and operating margin -17.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $36.31M | $34.87M | $24.09M | $4.35M | $228.43K |
| Growth | +4.11% | +44.75% | +454.42% | +1802.41% | +219.88% |
| Net income | $-5.98M | $-5.13M | $-4.51M | $-26.74M | $-12.44M |
| EPS (diluted) | — | $-7.32 | $-351.36 | $-1.76 | $-4.76 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$56.00+2411.21%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-5.20 vs —
SBFM news
All SBFM newsSunshine Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PPBTPurple Biotech Ltd. ADR | 1.53 | -4.09% | $1.86M | vs SBFM |
| PPCBPropanc Biopharma Inc. | 1.78 | +3.19% | $1.87M | vs SBFM |
| XRTXXORTX Therapeutics Inc. | 0.839 | -5.73% | $1.88M | vs SBFM |
| EOCNEocene Ltd. | 1.78 | +1.73% | $1.90M | vs SBFM |
| KALAKALA BIO Inc. | 2.71 | -10.28% | $1.74M | vs SBFM |
| GNPXGenprex Inc. | 1.45 | -13.17% | $1.94M | vs SBFM |
| DCOYDecoy Therapeutics Inc. | 0.8294 | -4.68% | $1.98M | vs SBFM |
| REVBRevelation Biosciences Inc. | 3.50 | -5.15% | $1.99M | vs SBFM |
Indexes, lists and sector
Sunshine Biopharma stock FAQ
What is Sunshine Biopharma's stock price today?
SBFM last traded at $2.23 as of Nov 20, 4:00 PM EST, down 5.11% on the day. Prices are delayed at least 15 minutes.
Does Sunshine Biopharma pay a dividend?
No. Sunshine Biopharma does not currently pay a regular cash dividend.
Who is Sunshine Biopharma's CEO?
Dr. Steve N. Slilaty Ph.D. is the chief executive officer of Sunshine Biopharma Inc., which has about 50 employees.
Has SBFM ever split its stock?
Yes. The most recent SBFM stock split was a 1-for-20 split on Oct 26, 2026.
What is the SBFM 52-week high?
The 52-week high for SBFM is $464.00 and the 52-week low is $2.23. The stock is currently 99.5% below its high.